Evommune, Inc. (EVMN) stock
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
$7.02−0.08 (-1.13%)
Close on Nov 17, 2026Market cap $254.77MP/E –Yield –
Evommune operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Evommune's operating income for the twelve months ending Sep 30, 2026 was -$121.89M. For fiscal 2025 it was -$81.07M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$81.07M | – |
| FY2024 | Dec 31, 2024 | -$70.01M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$33.33M | – |
| Q2 FY2026 | Jun 30, 2026 | -$34.90M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.95M | – |
| Q4 FY2025 | Dec 31, 2025 | -$29.72M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.33M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.99M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.03M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.45M | – |
| Q3 FY2024 | Sep 30, 2024 | -$16.52M | – |
See a number that looks wrong?